Outcomes in COVID-19 apilimod studies

0 0.5 1 1.5+ All studies -199% 1 141 Improvement, Studies, Patients Relative Risk Mortality -199% 1 141 RCTs -199% 1 141 Early -199% 1 141 Apilimod for COVID-19 c19early.org November 2025 Favorsapilimod Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Young (DB RCT) -199% 2.99 [0.12-72.1] death 1/71 0/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Early treatment -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk All studies -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk 1 apilimod COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors apilimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Young (DB RCT) -199% 2.99 [0.12-72.1] 1/71 0/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Early treatment -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk All studies -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk 1 apilimod COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Favors apilimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Young (DB RCT) -199% 2.99 [0.12-72.1] death 1/71 0/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Early treatment -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk All studies -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk 1 apilimod COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors apilimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Young (DB RCT) -109% 2.09 [0.40-11.0] no recov. 4/64 2/67 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.39 Early treatment -109% 2.09 [0.40-11.0] 4/64 2/67 109% higher risk All studies -109% 2.09 [0.40-11.0] 4/64 2/67 109% higher risk 1 apilimod COVID-19 recovery result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.39 Favors apilimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Young (DB RCT) -199% 2.99 [0.12-72.1] death 1/71 0/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Early treatment -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk All studies -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk 1 apilimod COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors apilimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Young (DB RCT) -199% 2.99 [0.12-72.1] 1/71 0/70 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Early treatment -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk All studies -199% 2.99 [0.12-72.1] 1/71 0/70 199% higher risk 1 apilimod COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Favors apilimod Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Young (DB RCT) -199% 2.99 [0.12-72.1] death 1/71 0/70 Improvement, RR [CI] Treatment Control Young (DB RCT) -100% 2.00 [0.19-21.6] death/hosp. 2/71 1/71 Young (DB RCT) -109% 2.09 [0.40-11.0] no recov. 4/64 2/67 Apilimod COVID-19 outcomes c19early.org November 2025 Favors apilimod Favors control